Ivabradine
- 18 October 2016
- book chapter
- Published by Springer Nature
- Vol. 243, 167-175
Abstract
Ivabradine is a blocker of the funny current channels in the sinoatrial node cells. This results in pure heart rate reduction when elevated without direct effect on contractility or on the vessels. It was tested in a large outcome clinical trial in stable chronic heart failure (CHF) with low ejection fraction, in sinus rhythm, on a contemporary background therapy including betablockers (SHIFT: Systolic Heart Failure Treatment with the If inhibitor Trial). The primary composite endpoint (cardiovascular mortality or heart failure hospitalization) was reduced by 18% whereas the first occurrence of heart failure hospitalizations was reduced by 26%. The effect was of greater magnitude in patients with baseline heart rate ≥75 beats per minute. Ivabradine improved also the quality of life and induced a reverse remodelling. The safety was overall good with an increase in (a)symptomatic bradycardia and visual side effects. The efficacy and tolerability were similar to those observed in the overall trial in subgroups with diabetes mellitus, low systolic blood pressure (SBP), renal dysfunction or chronic obstructive pulmonary disease (COPD). Ivabradine is indicated in CHF with systolic dysfunction, in patients in sinus rhythm with a heart rate ≥75 bpm in combination with standard therapy including betablocker therapy or when betablocker therapy is contraindicated or not tolerated (European Medicine Agency).Keywords
This publication has 22 references indexed in Scilit:
- Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF): A randomised studyInternational Journal of Cardiology, 2016
- Twenty-Four-Hour Heart Rate Lowering with Ivabradine in Chronic Heart Failure: Insights from the SHIFT Holter SubstudyEuropean Journal of Heart Failure, 2015
- Efficacy and Safety of Ivabradine in Patients with Chronic Systolic Heart Failure According to Blood Pressure Level in SHIFTEuropean Journal of Heart Failure, 2014
- Risk Following Hospitalization in Stable Chronic Systolic Heart FailureEuropean Journal of Heart Failure, 2013
- Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT StudyEuropean Heart Journal, 2012
- Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT studyEuropean Heart Journal, 2011
- Favourable Effects of Heart Rate Reduction with Intravenous Administration of Ivabradine in Patients with Advanced Heart FailureEuropean Journal of Heart Failure, 2008
- Funny channels in the control of cardiac rhythm and mode of action of selective blockersPharmacological Research, 2006
- Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failureJACC, 2000
- Influence of the force—frequency relationship on haemodynamics and left ventricular function in patients with non-failing hearts and in patients with dilated cardiomyopathyEuropean Heart Journal, 1994